Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06077760
Registration number
NCT06077760
Ethics application status
Date submitted
5/10/2023
Date registered
11/10/2023
Date last updated
7/06/2024
Titles & IDs
Public title
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
Query!
Secondary ID [1]
0
0
2023-504923-20
Query!
Secondary ID [2]
0
0
V940-002
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
INTerpath-002
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - V940
Other interventions - Pembrolizumab
Other interventions - Placebo
Experimental: V940 + Pembrolizumab - Participants will receive 1 mg of V940 via intramuscular (IM) injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via intravenous (IV) infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
Active Comparator: Placebo + Pembrolizumab - Participants will receive V940-matched placebo via IM injection once every 3 weeks for 9 doses PLUS 400 mg of pembrolizumab via IV infusion once every 6 weeks for up to 9 doses until disease recurrence or unacceptable toxicity or for a total treatment duration of up to approximately 1 year, whichever is sooner.
Other interventions: V940
IM injection
Other interventions: Pembrolizumab
IV infusion
Other interventions: Placebo
IM injection
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease- Free Survival (DFS)
Query!
Assessment method [1]
0
0
DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
Up to ~78 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [1]
0
0
Up to ~12 years
Query!
Secondary outcome [2]
0
0
Distant Metastasis-Free Survival (DMFS)
Query!
Assessment method [2]
0
0
DMFS is defined as the time from randomization to the first diagnosis of a distant metastasis as assessed by the investigator, or death due to any cause, whichever occurs first.
Query!
Timepoint [2]
0
0
Up to ~12 years
Query!
Secondary outcome [3]
0
0
Lung Cancer Specific Survival (LCSS)
Query!
Assessment method [3]
0
0
LCSS is defined as the time from randomization to death due to lung cancer.
Query!
Timepoint [3]
0
0
Up to ~12 years
Query!
Secondary outcome [4]
0
0
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
Query!
Assessment method [4]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. The change from baseline in global health status/quality of life (EORTC QLQ-C30 Items 29 and 30) combined score will be presented.
Query!
Timepoint [4]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [5]
0
0
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
Query!
Assessment method [5]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a worse level of physical functioning. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
Query!
Timepoint [5]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [6]
0
0
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30
Query!
Assessment method [6]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a worse level of role functioning. The change from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) combined score will be presented.
Query!
Timepoint [6]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [7]
0
0
Change from Baseline in the EORTC QLQ-C30 Dyspnea (Item 8) Score on the EORTC QLQ-C30
Query!
Assessment method [7]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question "Were you short of breath?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a worse level of dyspnea. The change from baseline in dyspnea (EORTC QLQ-C30 Item 8) score will be presented.
Query!
Timepoint [7]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [8]
0
0
Change from Baseline in the EORTC QLQ-Lung Cancer Questionnaire (LC24) Coughing (Items 31 and 52) Combined Score on the EORTC QLQ-LC24
Query!
Assessment method [8]
0
0
The EORTC QLQ-LC24 is a lung cancer specific health-related quality of life questionnaire. Participant responses to questions about coughing will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. A higher score indicates more coughing. The change from baseline in coughing (EORTC QLQ-LC24 Items 31 and 52) combined score will be presented.
Query!
Timepoint [8]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [9]
0
0
Change from Baseline in the EORTC QLQ-LC24 Chest Pain (Item 40) Score on the EORTC QLQ-LC24
Query!
Assessment method [9]
0
0
The EORTC QLQ-LC24 is a lung cancer specific health-related quality of life questionnaire. Participant responses to the question "Have you had pain in your chest?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. A higher score indicates more chest pain. The change from baseline in chest pain (EORTC QLQ-LC24 Item 40) score will be presented.
Query!
Timepoint [9]
0
0
Baseline and up to ~12 years
Query!
Secondary outcome [10]
0
0
Number of Participants Who Experience an Adverse Event (AE)
Query!
Assessment method [10]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [10]
0
0
Up to ~15 months
Query!
Secondary outcome [11]
0
0
Number of Participants Who Discontinue Study Treatment Due to an AE
Query!
Assessment method [11]
0
0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Query!
Timepoint [11]
0
0
Up to ~12 months
Query!
Eligibility
Key inclusion criteria
The main inclusion criteria include but are not limited to the following:
- Has surgically resected and histologically confirmed diagnosis of pathological Stage
II, IIIA, IIIB (N2) squamous or nonsquamous NSCLC as per American Joint Committee on
Cancer (AJCC) Eighth Edition guidelines.
- Has no evidence of disease before randomization.
- Has received at least one dose of adjuvant treatment with standard of care platinum
doublet chemotherapy.
- No more than 24 weeks have elapsed between surgical resection of curative intent and
the first dose of pembrolizumab.
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they
have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have
undetectable HBV viral load prior to randomization.
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV
viral load is undetectable at screening.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV
on anti-retroviral therapy (ART).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
The main exclusion criteria include but are not limited to the following:
- Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small
cell elements, or has a neuroendocrine tumor with large cell components or a
sarcomatoid carcinoma.
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease.
- Received prior neoadjuvant therapy for their current NSCLC diagnosis.
- Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis.
- Received prior therapy with an anti-programmed cell death 1 protein (PD-1),
anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another
stimulatory or coinhibitory T-cell receptor.
- Received prior systemic anticancer therapy including investigational agents within 4
weeks before randomization.
- Received a live or live-attenuated vaccine within 30 days before the first dose of
study intervention. Administration of killed vaccines are allowed.
- Has received an investigational agent or has used an investigational device within 4
weeks prior to study intervention administration.
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in
dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study medication.
- Known additional malignancy that is progressing or has required active treatment
within the past 5 years.
- Active autoimmune disease that has required systemic treatment in the past 2 years.
Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is
allowed.
- History of (noninfectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease.
- Active infection requiring systemic therapy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
21/12/2035
Query!
Actual
Query!
Sample size
Target
868
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0203) - Melbourne
Query!
Recruitment hospital [2]
0
0
St Vincent's Hospital-Oncology Clinical Trials ( Site 0202) - Melbourne
Query!
Recruitment hospital [3]
0
0
One Clinical Research ( Site 0200) - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
3065 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Idaho
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kentucky
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Montana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New Jersey
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Dakota
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oregon
Query!
Country [11]
0
0
Argentina
Query!
State/province [11]
0
0
Buenos Aires
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Santa Fe
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Caba
Query!
Country [14]
0
0
Canada
Query!
State/province [14]
0
0
Quebec
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Region M. De Santiago
Query!
Country [16]
0
0
Chile
Query!
State/province [16]
0
0
Valparaiso
Query!
Country [17]
0
0
Costa Rica
Query!
State/province [17]
0
0
San Jose
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Brno-mesto
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Ostrava Mesto
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Olomouc
Query!
Country [21]
0
0
Estonia
Query!
State/province [21]
0
0
Harjumaa
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Alsace
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Aquitaine
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Herault
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Maine-et-Loire
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Puy-de-Dome
Query!
Country [27]
0
0
Greece
Query!
State/province [27]
0
0
Thessaloniki
Query!
Country [28]
0
0
Hungary
Query!
State/province [28]
0
0
Bacs-Kiskun
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Baranya
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Somogy
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Friuli-Venezia Giulia
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Umbria
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Novara
Query!
Country [34]
0
0
Lithuania
Query!
State/province [34]
0
0
Kauno Apskritis
Query!
Country [35]
0
0
Lithuania
Query!
State/province [35]
0
0
Vilniaus Miestas
Query!
Country [36]
0
0
New Zealand
Query!
State/province [36]
0
0
Canterbury
Query!
Country [37]
0
0
New Zealand
Query!
State/province [37]
0
0
Auckland
Query!
Country [38]
0
0
Norway
Query!
State/province [38]
0
0
Akershus
Query!
Country [39]
0
0
Norway
Query!
State/province [39]
0
0
Rogaland
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Kujawsko-pomorskie
Query!
Country [41]
0
0
Poland
Query!
State/province [41]
0
0
Podkarpackie
Query!
Country [42]
0
0
Poland
Query!
State/province [42]
0
0
Podlaskie
Query!
Country [43]
0
0
Poland
Query!
State/province [43]
0
0
Wielkopolskie
Query!
Country [44]
0
0
Spain
Query!
State/province [44]
0
0
Barcelona
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Madrid, Comunidad De
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Madrid
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Malaga
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Sevilla
Query!
Country [49]
0
0
Taiwan
Query!
State/province [49]
0
0
Changhua
Query!
Country [50]
0
0
Taiwan
Query!
State/province [50]
0
0
Taipei
Query!
Country [51]
0
0
Taiwan
Query!
State/province [51]
0
0
Hsinchu
Query!
Country [52]
0
0
Taiwan
Query!
State/province [52]
0
0
Taichung
Query!
Country [53]
0
0
Taiwan
Query!
State/province [53]
0
0
Tainan
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
ModernaTX, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus
pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB
(with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is
that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to
disease-free survival (DFS) as assessed by the investigator.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06077760
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Toll Free Number
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-577-8839
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06077760
Download to PDF